375 related articles for article (PubMed ID: 11889082)
21. The evolution of knowledge on the pathophysiology of portal hypertension.
Rodés J; Escorcell A
Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():53-6. PubMed ID: 8899694
[No Abstract] [Full Text] [Related]
22. Endothelial cell dysfunction in microvasculature: relevance to disease processes.
Oda M; Han JY; Nakamura M
Clin Hemorheol Microcirc; 2000; 23(2-4):199-211. PubMed ID: 11321441
[TBL] [Abstract][Full Text] [Related]
23. Portal hypertension. Update on pathophysiology and management.
Chatila R
J Med Liban; 2001; 49(2):101-5. PubMed ID: 11910964
[TBL] [Abstract][Full Text] [Related]
24. Stellate cells and the "reversible component" of portal hypertension.
de Franchis R
Dig Liver Dis; 2000 Mar; 32(2):104-7. PubMed ID: 10975782
[No Abstract] [Full Text] [Related]
25. Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model.
Li J; Niu JZ; Wang JF; Li Y; Tao XH
World J Gastroenterol; 2005 Nov; 11(41):6483-8. PubMed ID: 16425420
[TBL] [Abstract][Full Text] [Related]
26. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension.
Ekataksin W; Kaneda K
Semin Liver Dis; 1999; 19(4):359-82. PubMed ID: 10643623
[TBL] [Abstract][Full Text] [Related]
27. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.
Kang SH; Kim MY; Baik SK
Hepatol Int; 2018 Feb; 12(Suppl 1):112-121. PubMed ID: 28698986
[TBL] [Abstract][Full Text] [Related]
28. [Physiopathologic basis of medical therapy of portal hypertension in cirrhosis].
Gatta A; Bolognesi M; Sacerdoti D; Merkel C
Ann Ital Med Int; 1996 Oct; 11 Suppl 2():39S-47S. PubMed ID: 9004819
[TBL] [Abstract][Full Text] [Related]
29. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
30. New cellular and molecular targets for the treatment of portal hypertension.
Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
[TBL] [Abstract][Full Text] [Related]
31. Etiology and pathophysiology of portal hypertension.
Reichen J
Z Gastroenterol; 1988 Sep; 26 Suppl 2():3-7. PubMed ID: 3055716
[TBL] [Abstract][Full Text] [Related]
32. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension.
Duong HT; Dong Z; Su L; Boyer C; George J; Davis TP; Wang J
Small; 2015 May; 11(19):2291-304. PubMed ID: 25641921
[TBL] [Abstract][Full Text] [Related]
33. Role of hepatic stellate cells in the pathogenesis of portal hypertension.
Marra F; Pinzani M
Nefrologia; 2002; 22 Suppl 5():34-40. PubMed ID: 12107915
[No Abstract] [Full Text] [Related]
34. Hepatic arterial flow becomes the primary supply of sinusoids following partial portal vein ligation in rats.
Yokoyama Y; Wawrzyniak A; Sarmadi AM; Baveja R; Gruber HE; Clemens MG; Zhang JX
J Gastroenterol Hepatol; 2006 Oct; 21(10):1567-74. PubMed ID: 16928218
[TBL] [Abstract][Full Text] [Related]
35. [Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis].
Garbuzenko DV
Ter Arkh; 2014; 86(2):90-5. PubMed ID: 24772515
[TBL] [Abstract][Full Text] [Related]
36. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Marrone G; Russo L; Rosado E; Hide D; García-Cardeña G; García-Pagán JC; Bosch J; Gracia-Sancho J
J Hepatol; 2013 Jan; 58(1):98-103. PubMed ID: 22989565
[TBL] [Abstract][Full Text] [Related]
37. [Hepatic microcirculation--with special emphasis on the microvascular alterations related to the development of portal hypertension and shunt].
Nakata K
Saishin Igaku; 1970 Aug; 25(8):1688-96. PubMed ID: 4917827
[No Abstract] [Full Text] [Related]
38. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
39. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
40. [Portal hypertension and the endothelium].
Marecková Z; Horký K
Cesk Fysiol; 2001 Feb; 50(1):19-24. PubMed ID: 11268558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
